IMM — ImmuPharma Income Statement
0.000.00%
Last trade - 00:00
- £9.79m
- £9.58m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.081 | 0.078 | 0.127 | 0.118 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 8.16 | 6.36 | 5.72 | 6.71 | 3.03 |
Operating Profit | -8.08 | -6.28 | -5.59 | -6.59 | -3.03 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7.96 | -6.74 | -7.25 | -8.94 | -4.46 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7.21 | -6.12 | -6.86 | -8.17 | -3.81 |
Net Income Before Extraordinary Items | |||||
Net Income | -7.21 | -6.12 | -6.86 | -8.17 | -3.81 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.21 | -6.12 | -6.86 | -8.17 | -3.81 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.052 | -0.04 | -0.034 | -0.029 | -0.013 |